PROCEPT BioRobotics is a surgical robotics company dedicated to advancing urology care. Co. develop, manufacture, and sell the AquaBeam Robotic System, an image-guided system for minimally invasive urologic surgery, primarily for treating benign prostatic hyperplasia (BPH). The AquaBeam system uses a single-use handpiece to deliver Aquablation therapy, which combines real-time imaging, personalized treatment planning, automated robotics, and heat-free waterjet ablation for precise prostate tissue removal. This therapy aims to provide effective, safe, and durable outcomes for men with lower urinary tract symptoms due to BPH, regardless of prostate size, shape, or surgeon experience. The PRCT YTD return is shown above.
The YTD Return on the PRCT YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether PRCT YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the PRCT YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|